Johnson & Johnson's Drug Acquired Via Momenta Deal Shows Encouraging Data In Fetal Disorder

  • Janssen, a unit of Johnson & Johnson JNJ, announced topline results from the proof-of-concept Phase 2 open-label UNITY trial for pregnant adults at high risk for severe hemolytic disease of the fetus and newborn.
  • In 2020, Johnson & Johnson shelled out $6.5 billion to acquire Momenta Pharmaceuticals Inc, gaining access to its lead product, nipocalimab.
  • HDFN is a rare condition that can cause life-threatening anemia in the fetus. 
  • It occurs when the blood types of a pregnant individual and their fetus are incompatible.
  • Most of the 14 pregnant patients who received once-weekly intravenous infusions of nipocalimab achieved a live birth at or after 32 weeks of gestation without requiring an intrauterine transfusion throughout their pregnancy. 
  • During the treatment period of approximately 20 weeks, nipocalimab demonstrated a safety profile that supports further development of the treatment in HDFN.
  • Over the roughly 20-week treatment period, nipocalimab’s safety profile supported further drug development in this fetal indication, J&J said. 
  • Katie Abouzahr, M.D., autoantibody portfolio development leader at Janssen Research & Development, said more data would be released at an upcoming scientific medical meeting while the company plans for a pivotal phase 3 study. 
  • Price Action: JNJ shares are down 0.86% at $163.20 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!